Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells

Journal of Drug Targeting

Volumn 22, Issue 1, 2014, Pages 57-66

  Zhou, Wenhu ^a   Zhou, Yanbin ^a   Wu, Jianping ^a   Liu, Zhenbao ^a   Zhao, Huanzhe ^a   Liu, Juewen ^a   Ding, Jinsong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Aptamer; Breast cancer; Cytotoxicity; Drug delivery; Nanoparticles; Tumor targeting; Vinorelbine

Indexed keywords

APTAMER; NANOPARTICLE; NAVELBINE; NUCLEOLIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LACTIC ACID; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOPROTEINS; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RNA-BINDING PROTEINS; VINBLASTINE;

EID: 84890395694     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.839683     Document Type: Article

References (35)

1. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011;61:409-18.
2. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010;17:173-6.
3. Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliver Rev 2010;62:203-30.
4. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60.
5. Gu FX, Karnik R, Wang AZ, et al. Targeted nanoparticles for cancer therapy. Nano Today 2007;2:14-21.
6. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82.
7. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002;83: 273-86.
8. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505-15.
9. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505-10.
10. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-22.
11. Fang X, Tan, W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Accounts Chem Res 2009;43:48-57.
12. Orava EW, Cicmil N, Gariepy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta 2010;1798:2190-200.
13. Bates PJ, Laber DA, Miller DM, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009;86:151-64.
14. Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011;32:8010-20.
15. Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as firstline and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-30.
16. You K, Niho S, Goto K, et al. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. Jpn J Clin Oncol 2004;34:206-9.
17. Zhang HY, Tang X, Li HY, Liu XL. A lipid microsphere vehicle for vinorelbine: stability, safety and pharmacokinetics. Int J Pharm 2008;348:70-9.
18. Zhang H, Wang Z, Gong W, et al. Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate. Int J Pharm 2011;414:56-62.
19. You J, Wan F, Cui F, et al. Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int J Pharm 2007;343:270-6.
20. Sanna V, Pintus G, Bandiera P, Anedda R. Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel ultrasound contrast agents. Mol Pharmaceutics 2011;8:748-57.
21. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007;28:869-76.
22. Brody JR, Calhoun ES, Gallmeier E, et al. Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media. Biotechniques 2004;37: 598-602.
23. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Rel 2012;161:175-87.
24. Watanabe T, Hirano K, Takahashi A, et al. Nucleolin on the cell surface as a new molecular target for gastric cancer treatment. Biol Pharm Bull 2010;33:796-803.
25. Gao H, Qian J, Cao S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012;33:5115-23.
26. Yu C, Hu Y, Duan J, et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One 2011;6:e24077.
27. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 2008;105: 17356-61.
28. Aravind A, Jeyamohan P, Nair R, et al. AS1411 aptamer tagged PLGAlecithinPEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 2012;109:2920-31.
29. Mosqueira VCF, Legrand P, Morgat J, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res 2001;18:1411-19.
30. Zhang N, Chittasupho C, Duangrat C, et al. PLGA nanoparticlepeptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjugate Chem 2007;19:145-52.
31. Gref R, Lück M, Quellec P, et al. 'Stealth'corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid Surf B 2000;18:301-13.
32. Duan Y, Sun X, Gong T, et al. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo. J Mater Sci: Mater Med 2006; 17:509-16.
33. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315-20.
34. Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomed-Nanotechnol 2009;5:323-33.
35. Soundararajan S, Wang L, Sridharan V, et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol 2009;76: 984-91.